| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1370554 | Bioorganic & Medicinal Chemistry Letters | 2015 | 4 Pages |
Abstract
Inflammatory bowel disease, including Crohn’s disease and ulcerative colitis, affects millions of people worldwide. CCR9 has been shown to be a key chemokine receptor mediating the local inflammatory responses in the GI tract. The CCR9 inhibitor Vercirnon advanced to phase 3 clinical trials, but carries several liabilities which we sought to improve.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Jing Zhang, Jan Romero, Audrey Chan, Jennifer Goss, Sabrina Stucka, Jason Cross, Brian Chamberlain, Mustafa Varoglu, Haoqun Chandonnet, Dominic Ryan, Blaise Lippa,